72 results about "Messenger RNA" patented technology

The invention relates to the technical field of biological information, and discloses a messenger RNA stability prediction method, model, device, equipment and medium, the method comprises the following steps: obtaining target sequence information of a target messenger RNA; acquiring at least two of the following target feature information based on the target sequence information by using a feature extraction module in the messenger RNA stability prediction model: first sequence feature information, Kozak sequence feature information, Motif attention feature information and manual feature information; and predicting the stability of the target messenger RNA based on the target feature information by using a prediction head in the messenger RNA stability prediction model. According to the method, the mRNA stability is predicted by fusing the universal sequence feature of the mRNA, the Kozak sequence feature of the learnable position weight, the Motif attention feature based on the hash k-mer and the manual feature, and the accuracy of mRNA stability prediction is improved.

A composition of matter includes an antisense phosphorodiamidate morpholino oligomer (MO) that includes an MO base sequence. The MO base sequence is arranged to bind a corresponding complementary base sequence of messenger RNA (mRNA) transcribed from one or more genes for the beta subunit of human chorionic gonadotropin (hCG-β). An inventive method, for suppressing intracellular synthesis of a beta subunit of human chorionic gonadotropin (hCG-β), includes introducing such an MO into one or more cells.

The present invention provides novel ionizable lipids and novel lipid nanoparticles comprising messenger RNA (mRNA) useful for the delivery of nucleic acids as defined herein, related pharmaceutical compositions or vaccines for use in human medicine or veterinary medicine, in particular for the treatment and / or prevention of cancer diseases.

The present invention provides, among other things, methods for purifying mRNA, which involves removing impurities from a messenger RNA preparation synthesized by large scale invitro transcription process (IVT), by precipitating the IVT-synthesized mRNA in a buffer comprising a denaturing salt in combination with a reducing agent, followed by capturing the precipitated mRNA and dissolving the captured mRNA into a solution to obtain purified mRNA.

A case for transporting a substance such as a messenger RNA vaccine, including a container, a damping material contained in the container and a storage structure immersed in the damping product, the storage structure forming cavities for receiving syringes containing said substance.

This application provides a method and apparatus for optimizing the codon sequence of human albumin, belonging to the field of data processing technology. Addressing the current problems of low synthesis efficiency and scarcity of human albumin drugs, it allows for the grouping of large datasets of human albumin amino acid sequences. An improved genetic optimization algorithm is then used to optimize the corresponding messenger RNA item by item, ultimately obtaining the optimal second target messenger RNA. When using this second target messenger RNA for protein expression to obtain the target recombinant human albumin, the expression efficiency of the host Pichia pastoris cells can be maximized, significantly improving the current synthesis efficiency of recombinant human albumin and greatly alleviating the problem of human albumin drug scarcity.

The present invention provides a pharmaceutical composition comprising an exosome encapsulating one or more cargo RNAs containing package RNA and one or more fusion proteins, wherein the nucleotide sequence of the package RNA is at least about 80%, about 85%, about 90%, about 95%, or about 100% identical to the nucleotide sequence of an elastin (ELN) gene or elastin messenger RNA (mRNA) also containing any isoform. Additionally, the present invention provides a method for treating an elastin deficiency-related disease in a subject using the pharmaceutical composition of the present invention.

Synthetic bacterial messenger RNA can be used to make autologous, allogeneic or direct nucleic acid cancer vaccines. Cancer cells are transfected in vitro or in vivo with mRNA obtained from DNA encoding immunogenic bacterial proteins. The immune response to cancer is generated by direct administration of the mRNA in vivo or administration of a vaccine made from cancer cells in vitro. Codon modification of the mRNA can optimize expression of the immunogenic polypeptide in cancer cells.

Provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.

The present application relates to the technical field of biological information, and discloses a messenger RNA stability prediction method, model, device, equipment and medium, the method comprises the following steps: obtaining target sequence information of target messenger RNA; using the feature extraction module in the messenger RNA stability prediction model, at least two of the following target feature information is obtained based on the target sequence information: first sequence feature information, Kozak sequence feature information, Motif attention feature information and manual feature information; using the prediction head in the messenger RNA stability prediction model, predicting the stability of the target messenger RNA based on the target feature information. The present application predicts the mRNA stability by fusing the general sequence features of mRNA, the learnable position weight Kozak sequence features, the Motif attention features based on hash k-mer and the manual features, thereby improving the accuracy of mRNA stability prediction.

The present invention relates to compositions comprising RNA, preferably messenger RNA (mRNA), more preferably self-amplifying RNA (saRNA), and polymers, in particular cationic polymers, such as polyethylenimine (PEI), poly-L-Lysin (PEL), polyvinylamine (PVA) or polyallylamine (PAA), where individual RNA molecules are present in solution. In the formulations, the RNA is preferentially present in the form of monomers, dimers, timers or oligomers, but not as aggregates comprising a large number of RNA molecules per aggregate, in particular large polyplex nanoparticles. The formulations display improved transfection efficacy and they can be used for delivery of RNA to a subject, where they have an improved dose response relationship in comparison to formulations where large aggregates in the form of polyplex nanoparticles are present.

The present invention relates to a method for tailing in vitro transcribed (IVT) messenger RNA (mRNA) containing modified ribonucleotides, the method comprising adding the IVT mRNA to a tailing polymerase in a reaction buffer containing up to 30 mM of an alkali metal salt and at least 5 mM of a reducing agent.

The disclosure features compositions or systems and uses thereof, comprising a first polynucleotide encoding a target molecule, optionally a second polynucleotide encoding an effector, repressor, or endonuclease molecule; optionally a recognition or cleavage site in the first or second polynucleotide, and optionally a repressor / effector binding site in the first polynucleotide. The disclosure also features compositions or systems and uses thereof, comprising a messenger RNA (mRNA) comprising (i) an open reading frame encoding a polypeptide, and (ii) at least six miR142 target sites.

The present disclosure provides a method for treating angiogenesis in a target tissue in a subject. According to the present disclosure, there is provided a method which includes administering an immunogenic composition containing messenger RNA (mRNA) that encodes LRG1 or a fragment thereof to the subject.

Abstract The present invention relates to the mRNA vaccine of coronavirus spike protein with deletion of glycosites in the receptor binding domain (RBD), the subunit 1 (S1) domain, or the subunit 2 (S2) domain, or a combination thereof. The vaccine elicits broadly protective immune responses coronavirus and variants thereof. Abstract

The present disclosure relates to a method of determining the presence of at least one messenger RNA (mRNA) molecule in a composition, the method comprising: (a) reverse transcription of the at least one mRNA molecule to obtain a template comprising at least one first strand of complementary DNA (cDNA); (b) generating at least one double-stranded cDNA molecule from the template; (c) amplifying the at least one double-stranded cDNA molecule; (d) digesting the at least one amplified double-stranded cDNA molecule with at least one restriction enzyme to obtain a test cDNA fragment; (e) separating the test cDNA fragments so as to form a test cDNA fragment map; and (f) comparing the test cDNA fragment map to a control cDNA fragment map wherein the at least one mRNA molecule is present in the composition when the test cDNA fragment map comprises the control cDNA fragment map. Also disclosed are methods of quantifying and / or assessing the integrity of at least one mRNA molecule in a composition, processes of making a composition comprising at least one mRNA molecule and a primer pair for use in the methods of the invention.

Disclosed herein are lipid nanoparticles comprising messenger RNA (mRNA) molecules encoding deepitoped Ara h 1 and / or de-epitoped Ara h 2, vaccines comprising the nanoparticles and methods for inducing desensitization to peanuts and / or immunomodulation of a response to peanuts in a subject allergic to peanuts.

The present invention relates generally to lipids, lipid nanoparticle formulations, and methods for their use in delivering nucleic acids, such as messenger RNA.

The present disclosure provides RNA-lipid particles and formulations comprising novel lipids and therapeutic agents, methods of making RNA-lipid particles, and methods of delivering and / or administering RNA-lipid particles. In particular, the present disclosure provides RNA-lipid particles comprising a polyomithine-based lipid conjugate or conjugate of polyomithine and a lipid-like material, and RNA (e.g., single-stranded messenger RNA encoding a peptide or protein of interest), and methods of making RNA-lipid particles. Particles comprising mRNA and polyomithine are delivered to target tissues following administration via intramuscular, intravenous, or subcutaneous routes.

This invention provides an improved in vitro transcription method that produces early-termination transcripts and full-length mRNA transcripts that do not contain double-stranded mRNA. [Solution] The present invention provides a method for preparing DNA sequences optimized as templates for in vitro transcription of mRNA. These DNA sequences are optimized to avoid premature termination of transcription by RNA polymerase. The present invention also provides a method for preparing optimized DNA sequences containing one or more termination signals at the 3' end to reduce or prevent non-template "run-off" transcription.

The present disclosure provides methods and compositions for improving the in vitro transcription (IVT) of messenger RNA (mRNA) using SP6, T7, or KP34 RNA polymerase. In particular, the present disclosure provides in vitro transcription templates with optimized nucleic acid sequences specific for use with SP6, T7, or KP34 RNA polymerase that improve mRNA transcript yield and / or reduce amounts of dsRNA.

The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNA) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, and methods of eliciting an immune response by administering the same, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w / w) to the mRNA encoding the influenza B virus. In particular, the disclosure relates to mRNA encoding these antigens formulated into lipid nanoparticles (LNPs).

Lipid nanoparticle compositions comprising a payload, a helper lipid, a sterol, a PEG lipid, an ionizable lipid, a permanent cationic lipid are provided. Also provided herein is a method of delivering a payload to cells in the lung of a subject by intravenous administration, and a method of treating and / or preventing a lung disease in a subject in need thereof by intravenous administration. Also provided is a method for quantifying the amount of capped messenger RNA (mRNA) in an mRNA sample, the method comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase, and separating the capped mRNA and uncapped mRNA using chromatography.

The present disclosure provides, inter alia, single sample multi-attribute methods for the simultaneous identification and / or quantification of RNA capping and tailing modifications. The present disclosure provides, inter alia, oligonucleotides comprising RNA bases and DNA bases complementary to the 5'and 3 'ends of RNA. Provided herein is a method of making an RNA for therapeutic use, the RNA having a quantitative percentage of capped mRNA and uncapped mRNA and specified poly A tail length and polydispersity. Also provided herein is a quality control assay for manufacturing batches.

This application relates to a composition comprising lipid nanoparticles (LNPs) that encapsulate ribonucleic acid (RNA) molecules such as messenger RNA molecules, and stabilized with a heat-stable formulation comprising one or more thermoreversible gelling agents, one or more heat-stabilizing excipients, and / or buffers, pharmaceutically acceptable salts, disaccharides, surfactants, and chelating agents. Methods for preparing and using the stabilized composition, as well as methods for stabilizing a composition containing RNA-encapsulated LNPs, are also provided.

A method of isolating and separating a target macromolecule, such DNA (double stranded or single stranded), RNA (double stranded or single stranded), messenger RNA, or other oligonucleotide or oligonucleoside, from a sample by binding the target macromolecule to an affinity ligand that is bound to a surface is disclosed. The method may be employed in chromatography or any other of the separation sciences.

To provide an effective, reliable and efficient method for producing high-quality RNA in a large scale for therapeutic use.SOLUTION: A method of capping and tailing a purified in vitro transcribed messenger RNA (mRNA) preparation, wherein the method comprises enzymatically capping and tailing the mRNA in a reaction-buffer comprising 1mM having a concentration of 0. 0mM to 1. MgCl2 and having a pH of 6.0 to 7.8.SELECTED DRAWING: Figure 1

The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and / or one or more influenza virus neuraminidase (NA) proteins.